- Home
- ABTC vs NAMS Comparison
ABTC vs NAMS Comparison
Compare ABTC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | NAMS |
|---|---|---|
| Founded | 2024 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABTC | NAMS |
|---|---|---|
| Price | $1.56 | $32.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $4.00 | ★ $46.56 |
| AVG Volume (30 Days) | ★ 11.7M | 722.9K |
| Earning Date | 11-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $122,500,000.00 | $35,243,000.00 |
| Revenue This Year | $159.82 | N/A |
| Revenue Next Year | $97.44 | $10.46 |
| P/E Ratio | $8.35 | ★ N/A |
| Revenue Growth | ★ 88.52 | 4.91 |
| 52 Week Low | $1.48 | $14.06 |
| 52 Week High | $10.24 | $42.00 |
Technical Indicators
Market Signals| Indicator | ABTC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 43.80 |
| Support Level | $1.48 | $30.17 |
| Resistance Level | $1.61 | $32.45 |
| Average True Range (ATR) | 0.09 | 1.60 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 14.33 | 35.88 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure platform. The Company delivers institutional-grade exposure to Bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.